Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Colorectal Neoplasms

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 83 articles: HTML format

Single Articles

October 2024
1. VAN DEN PUTTELAAR R, Shi KS, Smith R, Zhao J, et al
   Implications of the initial braidwood v. Becerra ruling for colorectal cancer outcomes: a modeling study.
   J Natl Cancer Inst. 2024 Oct 3:djae244. doi: 10.1093.
   PubMed     Abstract available
   
   
   September 2024
2. ZHAO J, Xue E, Zhou S, Zhang M, et al
   Allostatic Load, Genetic Susceptibility, Incidence Risk, and All-cause Mortality of Colorectal Cancer.
   J Natl Cancer Inst. 2024 Sep 13:djae223. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. GARG A, Damgacioglu H, Sigel K, Nyitray AG, et al
   Future patterns in burden and incidence of squamous cell carcinoma of the anus in the United States, 2001-2035.
   J Natl Cancer Inst. 2024;116:1508-1512.
   PubMed     Abstract available
   
   
   
4. DESHMUKH AA, Lin YY, Damgacioglu H, Shiels M, et al
   Recent and projected incidence trends and risk of anal cancer among people with HIV in North America.
   J Natl Cancer Inst. 2024;116:1450-1458.
   PubMed     Abstract available
   
   
   August 2024
5. CHENG E, Ou FS, Gatten C, Ma C, et al
   Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer.
   J Natl Cancer Inst. 2024 Aug 30:djae213. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. BROWN JC, Ma C, Shi Q, Couture F, et al
   Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
   J Natl Cancer Inst. 2024 Aug 24:djae203. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. LIANG PS, Bhatt D
   Modeling disparities in colorectal cancer outcomes: colonoscopy follow-up and quality are key.
   J Natl Cancer Inst. 2024 Aug 8:djae176. doi: 10.1093.
   PubMed    
   
   
   
8. RIM SH, Beer L, Saraiya M, Tie Y, et al
   Prevalence of anal cytology screening among persons with HIV and lack of access to high-resolution anoscopy at HIV care facilities.
   J Natl Cancer Inst. 2024;116:1319-1332.
   PubMed     Abstract available
   
   
   
9. GUPTA A, O'Callaghan CJ, Zhu L, Jonker DJ, et al
   The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17.
   J Natl Cancer Inst. 2024;116:1313-1318.
   PubMed     Abstract available
   
   
   
10. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available
    
    
    
11. BERRY E, Hostetter J, Bachtold J, Zamarripa S, et al
    Evaluating colonoscopy quality by performing provider type.
    J Natl Cancer Inst. 2024;116:1264-1269.
    PubMed     Abstract available
    
    
    July 2024
12. ALAGOZ O, May FP, Doubeni CA, Fendrick AM, et al
    Impact of racial disparities in follow-up and quality of colonoscopy on colorectal cancer outcomes.
    J Natl Cancer Inst. 2024 Jul 24:djae140. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
13. TSAI YY, Nair KG, Barot SV, Xiang S, et al
    Differences in Tumor-Associated T cell receptor repertoires between Early-Onset and Average-Onset colorectal cancer.
    J Natl Cancer Inst. 2024 Jun 20:djae143. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. SONG Y, Loomans-Kropp H, Baugher RN, Somerville B, et al
    Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome.
    J Natl Cancer Inst. 2024;116:957-965.
    PubMed     Abstract available
    
    
    
15. YATES J, Schaufelberger H, Steinacher R, Schar P, et al
    DNA-methylation variability in normal mucosa: a field cancerization marker in patients with adenomatous polyps.
    J Natl Cancer Inst. 2024;116:974-982.
    PubMed     Abstract available
    
    
    
16. RANSOHOFF DF
    Evaluating a blood test for Colon cancer screening: how simulation modeling can inform clinical policy making and research.
    J Natl Cancer Inst. 2024 Jun 6:djae125. doi: 10.1093.
    PubMed    
    
    
    
17. NASCIMENTO DE LIMA P, Van Den Puttelaar R, Knudsen AB, Hahn AI, et al
    Characteristics of a cost-effective blood test for colorectal cancer screening.
    J Natl Cancer Inst. 2024 Jun 6:djae124. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
18. HOCHSTER HS, Catalano P, Weitz M, Mitchell EP, et al
    Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208).
    J Natl Cancer Inst. 2024 May 22:djae114. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. CORONADO GD, Bienen L, Burnett-Hartman A, Lee JK, et al
    Maximizing scarce colonoscopy resources: the crucial role of stool-based tests.
    J Natl Cancer Inst. 2024;116:647-652.
    PubMed     Abstract available
    
    
    April 2024
20. SUN J, Zhao J, Zhou S, Li X, et al
    Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer.
    J Natl Cancer Inst. 2024 Apr 22:djae089. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. FANG A, Ugai T, Gurjao C, Zhong R, et al
    Alcohol and colorectal cancer risk subclassified by mutational signatures of DNA mismatch repair deficiency.
    J Natl Cancer Inst. 2024 Apr 4:djae078. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
22. BEVER AM, Hang D, Lee DH, Tabung FK, et al
    Metabolomic signatures of inflammation and metabolic dysregulation in relation to colorectal cancer risk.
    J Natl Cancer Inst. 2024 Mar 1:djae047. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. GOPALANI SV, Saraiya M, Huang B, Tucker TC, et al
    Population-level incidence of HPV-positive oropharyngeal, cervical, and anal cancers by smoking status.
    J Natl Cancer Inst. 2024 Mar 1:djae054. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
24. GOPALANI SV, Senkomago V, Rim SH, Saraiya M, et al
    Human papillomavirus-associated anal squamous cell carcinoma: sociodemographic, geographic, and county-level economic trends in incidence rates-United States, 2001-2019.
    J Natl Cancer Inst. 2024;116:275-282.
    PubMed     Abstract available
    
    
    
25. MAHLA RS
    RE: Autoimmune disease and the risk of anal cancer in the US elderly population.
    J Natl Cancer Inst. 2024;116:338-339.
    PubMed    
    
    
    
26. HOWLADER N, Bhattacharya M, Scoppa S, Miller D, et al
    Cancer and COVID-19: US cancer incidence rates during the first year of the pandemic.
    J Natl Cancer Inst. 2024;116:208-215.
    PubMed     Abstract available
    
    
    
27. SONG M, Engels EA, Clarke MA, Kreimer AR, et al
    Autoimmune disease and the risk of anal cancer in the US population aged 66 years and over.
    J Natl Cancer Inst. 2024;116:309-315.
    PubMed     Abstract available
    
    
    January 2024
28. HAAS CB, Engels EA, Palefsky JM, Clarke MA, et al
    Severe anal intraepithelial neoplasia trends and subsequent invasive anal cancer in the United States.
    J Natl Cancer Inst. 2024;116:97-104.
    PubMed     Abstract available
    
    
    
29. STAR J, Siegel RL, Minihan AK, Smith RA, et al
    Colorectal cancer screening test exposure patterns in US adults ages 45-49 years, 2019-2021.
    J Natl Cancer Inst. 2024 Jan 4:djae003. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
30. JABBOUR SK, Hochster HS
    Evolving paradigms in locally advanced rectal cancer: the means justify the ends.
    J Natl Cancer Inst. 2023;115:1439-1441.
    PubMed    
    
    
    
31. KENNECKE HF, Auer R, Cho M, Dasari NA, et al
    NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer.
    J Natl Cancer Inst. 2023;115:1457-1464.
    PubMed     Abstract available
    
    
    
32. PESANTEZ D, Ten Hoorn S, Machado I, Garcia-Albeniz X, et al
    Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
    J Natl Cancer Inst. 2023;115:1497-1505.
    PubMed     Abstract available
    
    
    August 2023
33. CHEN Z, Song W, Shu XO, Wen W, et al
    Novel insights into genetic susceptibility for colorectal cancer from transcriptome-wide association and functional investigation.
    J Natl Cancer Inst. 2023 Aug 26:djad178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. REIF DE PAULA T, Keller DS
    A National Evaluation of Adjuvant Chemotherapy in pT4N0M0 Colon Cancer from the National Cancer Database.
    J Natl Cancer Inst. 2023 Aug 16:djad164. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. DANIELS JP, Freedland SJ, Gresham G
    The growing implications of obesity for prostate cancer risk and mortality: where do we go from here?
    J Natl Cancer Inst. 2023 Aug 16:djad140. doi: 10.1093.
    PubMed    
    
    
    
36. HELTE E, Save-Soderbergh M, Larsson SC, Martling A, et al
    Disinfection by-products in drinking water and risk of colorectal cancer: a population-based cohort study.
    J Natl Cancer Inst. 2023 Aug 8:djad145. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. BYRD DA, Fan W, Greathouse KL, Wu MC, et al
    The intratumor microbiome is associated with microsatellite instability.
    J Natl Cancer Inst. 2023;115:989-993.
    PubMed     Abstract available
    
    
    July 2023
38. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
    Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome.
    J Natl Cancer Inst. 2023;115:853-860.
    PubMed     Abstract available
    
    
    
39. ARONSON M, Gryfe R, Choi YH, Semotiuk K, et al
    Evaluating colonoscopy screening intervals in patients with Lynch syndrome from a large Canadian registry.
    J Natl Cancer Inst. 2023;115:778-787.
    PubMed     Abstract available
    
    
    June 2023
40. HURWITZ LM, Dogbe N, Hughes Barry K, Koutros S, et al
    Obesity and prostate cancer screening, incidence, and mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2023 Jun 29:djad113. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. YEN T, Patel SG
    Symptoms and early-onset colorectal cancer: red flags are common flags!
    J Natl Cancer Inst. 2023 Jun 24:djad093. doi: 10.1093.
    PubMed    
    
    
    May 2023
42. BREGNI G, Trevisi E, Saude Conde R, Vanhooren M, et al
    Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.
    J Natl Cancer Inst. 2023;115:505-513.
    PubMed     Abstract available
    
    
    
43. BILLER LH, Ng K
    The "Scope" of Colorectal Cancer Screening in Lynch Syndrome: Is There an Optimal Interval?
    J Natl Cancer Inst. 2023 May 4:djad074. doi: 10.1093.
    PubMed    
    
    
    
44. FRITZ CDL, Otegbeye EE, Zong X, Demb J, et al
    Red-flag Signs and Symptoms for Earlier Diagnosis of Early-Onset Colorectal Cancer.
    J Natl Cancer Inst. 2023 May 4:djad068. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2023
45. CORONADO GD, Ferrari RM, Barnes A, Castaneda SF, et al
    Characteristics of Patient Navigation Programs in the Cancer Moonshot ACCSIS Colorectal Cancer Screening Initiative.
    J Natl Cancer Inst. 2023 Feb 22:djad032. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. CROSS AJ, Gunter MJ
    Ultra-processed foods and colorectal neoplasia: is there a link?
    J Natl Cancer Inst. 2023;115:117-119.
    PubMed    
    
    
    
47. SELBY K, Sedki M, Levine E, Kamineni A, et al
    Test performance metrics for breast, cervical, colon and lung cancer screening: a systematic review.
    J Natl Cancer Inst. 2023 Feb 8:djad028. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2023
48. VOS JAM, Sert E, Busschers WB, Duineveld LAM, et al
    Detection of colon cancer recurrences during follow-up care by general practitioners versus surgeons.
    J Natl Cancer Inst. 2023 Jan 30:djad019. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. DAVIS LE, Mahar AL, Strumpf EC
    Agreement between individual and neighbourhood income measures in patients with colorectal cancer in Canada.
    J Natl Cancer Inst. 2023 Jan 27:djad017. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. MA W, Walker MM, Thuresson M, Roelstraete B, et al
    Cancer risk in patients with diverticular disease: A nationwide cohort study.
    J Natl Cancer Inst. 2023;115:62-70.
    PubMed     Abstract available
    
    
    
51. ROMESSER PB, Sanchez-Vega F, Joshua Smith J
    A methylation-based prognostic signature in stage II colorectal patients: Considerations for clinical adoption.
    J Natl Cancer Inst. 2023;115:8-11.
    PubMed    
    
    
    December 2022
52. HANG D, Wang L, Fang Z, Du M, et al
    Ultra-processed food consumption and risk of colorectal cancer precursors: results from three prospective cohorts.
    J Natl Cancer Inst. 2022 Dec 7:djac221. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2022
53. MURPHY N, Newton CC, Song M, Papadimitriou N, et al
    Body Mass Index and Molecular Subtypes of Colorectal Cancer.
    J Natl Cancer Inst. 2022 Nov 29:djac215. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. COLDITZ GA
    Combined individual participant data: highest level evidence on obesity and colorectal cancer molecular subtypes.
    J Natl Cancer Inst. 2022 Nov 29:djac216. doi: 10.1093.
    PubMed    
    
    
    
55. GALLICCHIO L, Devasia TP, Tonorezos E, Mollica MA, et al
    Estimation of the Number of Individuals Living With Metastatic Cancer in the United States.
    J Natl Cancer Inst. 2022;114:1476-1483.
    PubMed     Abstract available
    
    
    October 2022
56. SHIH YT, Xu Y, Bradley C, Giordano SH, et al
    Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.
    J Natl Cancer Inst. 2022;114:1392-1399.
    PubMed     Abstract available
    
    
    September 2022
57. YU H, Wang X, Bai L, Tang G, et al
    DNA Methylation Profile in CpG-depleted Regions Uncovers a High-Risk Subtype of Early-stage Colorectal Cancer.
    J Natl Cancer Inst. 2022 Sep 28. pii: 6726193. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. ZHANG ER, Pfeiffer RM, Austin A, Clarke MA, et al
    Impact of HIV on Anal Squamous Cell Carcinoma Rates in the United States, 2001-2015.
    J Natl Cancer Inst. 2022;114:1246-1252.
    PubMed     Abstract available
    
    
    June 2022
59. CASTILHO JL, Bian A, Jenkins CA, Shepherd BE, et al
    CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.
    J Natl Cancer Inst. 2022;114:854-862.
    PubMed     Abstract available
    
    
    
60. MOSS JL, Pinto CN, Srinivasan S, Cronin KA, et al
    Enduring Cancer Disparities by Persistent Poverty, Rurality, and Race: 1990-1992 to 2014-2018.
    J Natl Cancer Inst. 2022;114:829-836.
    PubMed     Abstract available
    
    
    
61. GOLDBERG RM, Adams R, Buyse M, Eng C, et al
    Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.
    J Natl Cancer Inst. 2022;114:819-828.
    PubMed     Abstract available
    
    
    May 2022
62. 
    Correction to: Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
    J Natl Cancer Inst. 2022 May 20. pii: 6590000. doi: 10.1093.
    PubMed    
    
    
    
63. CASTANON A, Parmar D, Massat N, Sasieni P, et al
    Benefit of biennial faecal occult blood screening on colorectal cancer in England: A population-based case-control study.
    J Natl Cancer Inst. 2022 May 16. pii: 6586300. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. TIAN Y, Kim AE, Bien SA, Lin Y, et al
    Genome-Wide Interaction Analysis of Genetic Variants with Menopausal Hormone Therapy for Colorectal Cancer Risk.
    J Natl Cancer Inst. 2022 May 5. pii: 6581085. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2022
65. LADABAUM U, Church TR, Feng Z, Ransohoff DF, et al
    Counting Advanced Pre-Cancerous Lesions as True Positives When Determining Colorectal Cancer Screening Test Specificity.
    J Natl Cancer Inst. 2022 Feb 4. pii: 6522121. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. HEIN DM, Deng W, Bleile M, Kazmi SA, et al
    Racial and Ethnic Differences in Genomic Profiling of Early-Onset Colorectal Cancer.
    J Natl Cancer Inst. 2022 Feb 2. pii: 6520467. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2022
67. LEE LH, Davis L, Ylagan L, Omilian AR, et al
    Identification of a Subset of Stage I Colorectal Cancer Patients with High Recurrence Risk.
    J Natl Cancer Inst. 2022 Jan 30. pii: 6517508. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. MURPHY N, Song M, Papadimitriou N, Carreras-Torres R, et al
    Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis.
    J Natl Cancer Inst. 2022 Jan 20. pii: 6512063. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. ARCHAMBAULT AN, Jeon J, Lin Y, Thomas M, et al
    Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study.
    J Natl Cancer Inst. 2022 Jan 13. pii: 6506525. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. SHANKARAN V, Unger JM, Darke AK, Suga JM, et al
    S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients.
    J Natl Cancer Inst. 2022 Jan 4. pii: 6492636. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. GIOVANNUCCI E
    Molecular Biologic and Epidemiologic Insights for Preventability of Colorectal Cancer.
    J Natl Cancer Inst. 2022 Jan 3. pii: 6493343. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2021
72. WERNLY S, Datz C, Wernly B
    RE: Long-Term Colorectal Cancer Incidence and Mortality After Colonoscopy Screening According to Individuals' Risk Profiles.
    J Natl Cancer Inst. 2021 Dec 25. pii: 6483088. doi: 10.1093.
    PubMed    
    
    
    November 2021
73. JIN Z, Dixon JG, Fiskum JM, Parekh HD, et al
    Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.
    J Natl Cancer Inst. 2021;113:1693-1704.
    PubMed     Abstract available
    
    
    
74. CERCEK A, Chatila WK, Yaeger R, Walch H, et al
    A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers.
    J Natl Cancer Inst. 2021;113:1683-1692.
    PubMed     Abstract available
    
    
    
75. ENG C, Hochster H
    Early-Onset Colorectal Cancer: The Mystery Remains.
    J Natl Cancer Inst. 2021;113:1608-1610.
    PubMed    
    
    
    
76. YIN J, Cohen R, Jin Z, Liu H, et al
    Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.
    J Natl Cancer Inst. 2021;113:1705-1713.
    PubMed     Abstract available
    
    
    
77. JOSHI AD, Chan AT
    Racial Differences in Epigenetic Aging of the Colon: Implications for Colorectal Cancer.
    J Natl Cancer Inst. 2021;113:1618-1619.
    PubMed    
    
    
    
78. DEVALL M, Sun X, Yuan F, Cooper GS, et al
    Racial Disparities in Epigenetic Aging of the Right vs Left Colon.
    J Natl Cancer Inst. 2021;113:1779-1782.
    PubMed     Abstract available
    
    
    October 2021
79. LIPSYC-SHARF M, Zhang S, Ou FS, Ma C, et al
    Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Natl Cancer Inst. 2021 Oct 12. pii: 6390822. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2021
80. POST CCB, Stelloo E, Smit VTHBM, Ruano D, et al
    Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer.
    J Natl Cancer Inst. 2021;113:1212-1220.
    PubMed     Abstract available
    
    
    August 2021
81. BREUER E, Hebeisen M, Schneider MA, Roth L, et al
    Site of Recurrence and Survival After Surgery for Colorectal Peritoneal Metastasis.
    J Natl Cancer Inst. 2021;113:1027-1035.
    PubMed     Abstract available
    
    
    April 2021
82. WAGNER AD, Grothey A, Andre T, Dixon JG, et al
    Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
    J Natl Cancer Inst. 2021;113:400-407.
    PubMed     Abstract available
    
    
    
83. ZAANAN A, Henriques J, Cohen R, Sefrioui D, et al
    Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin.
    J Natl Cancer Inst. 2021;113:496-500.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.